Astellas Pharma Inc risk profile
35 Normal where most of the sector sits
Measured 1 September 2026 from YPH's filed statements. Recomputed nightly.
35 (Normal), driven by Market expectation at 100, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 100 | Acute | Volatile | One-year price volatility — 115.3% |
| Operating pressure | 10 | Contained | Easing | Operating-margin drift — +9.1 percentage points |
| Cash conversion | 15 | Contained | Easing | Capital spending against operating cash — 0.15x |
| Leverage and coverage | 16 | Contained | Easing | Current ratio — 1.17x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for Astellas Pharma Inc